Although clinical benefit is observed for a small proportion (approximately 5–20%) of breast cancer patients, emerging evidence shows that selecting patients based on immune parameters such as a high TIL score and high PD-L1 expression may modestly improve response rates (Emens et al. 2019). Here, CD274 is linked to breast carcinoma.